Lactobacillus reuteri HYZQF-1 and its application in preparing alcohol sobering and liver protecting products

Abstract

The present invention belongs to the field of microbial technology, and specifically relates to Lactobacillus reuteri HYZQFxia-1 and its application in the preparation of products for relieving hangover and protecting the liver. The Lactobacillus reuteri HYZQFxia-1 provided by the present invention is preserved in the Guangdong Provincial Culture Collection Center of Microorganisms. The preservation date is July 8, 2024, and the preservation number is GDMCC NO: 64833. While having the effects of regulating the balance of intestinal flora and promoting human digestion and absorption, this strain also has the effect of relieving hangover and protecting the liver, and can effectively alleviate the absorption of alcohol by the body, thereby alleviating and improving the discomfort after drinking. Administering 45 billion of the strain and 300 mg of the metabolite of the present invention per day can continuously provide endogenous essential amounts of mucopolysaccharides, ornithine, lactacin, and lecithin during the intestinal reproduction and growth process, which can relieve hangover and protect the liver and maintain the health of the body.

Description

Technical Field

[0001] The present invention belongs to the field of microbial technology, and particularly relates to Lactobacillus reuteri HYZQFxia-1 and its application in the preparation of products for relieving hangover and protecting the liver. Background Art

[0002] Disclosing the information of this background art section is only intended to increase the understanding of the overall background of the present invention, and is not necessarily regarded as an admission or an implication in any form that this information constitutes the prior art already known to those of ordinary skill in the art.

[0003] The liver is the largest glandular organ in the human body and plays a role in participating in the body's metabolism and detoxification. At the same time, it is also vulnerable to the effects of many drugs, chemicals, environmental pollutants and infections.

[0004] Alcohol is one of the essential beverages in life. Alcohol is contained in wine. Excessive drinking can change people's moods and behaviors and cause drunkenness. After getting drunk, there are often headaches, dizziness, poor self-control, thirst, dehydration, uncoordinated movements, incoherent speech, dilated pupils, decreased blood pressure, increased heart rate, urinary and fecal incontinence and other phenomena. The liver becomes the most severely damaged organ because it can metabolize alcohol. Alcoholic Liver Disease (ALD) is a type of liver disease characterized by excessive drinking as the main cause and different clinicopathological changes such as fatty liver, hepatitis, cirrhosis and liver cancer.

[0005] Excessive drinking has become a common public health problem, and the harm to the human body caused by excessive drinking has attracted wide attention in society. Therefore, the research and development of products for relieving discomfort after drinking and protecting the liver from alcohol has become a research hotspot in the medical field.

[0006] Currently, the products for relieving hangover and protecting the liver are mainly products such as silymarin and naloxone. These products have slow effects and are not obvious in terms of sobering up, relieving hangover, alleviating discomfort after drinking and protecting the liver. The role of probiotics in relieving hangover and protecting the liver is mainly manifested in regulating the intestinal flora, repairing the intestinal barrier and increasing the activity of liver enzymes. Currently, no probiotic preparations or products with the effect of relieving hangover and protecting the liver have been found. Summary of the Invention

[0007] In order to solve the deficiencies of the prior art, the present invention provides Lactobacillus reuteri HYZQFxia-1 and its application in the preparation of products for relieving hangover and protecting the liver. Lactobacillus reuteri HYZQFxia-1 provided by the present invention can not only regulate the balance of intestinal flora and promote human digestion and absorption, but also has the effect of relieving hangover and protecting the liver.

[0008] In order to achieve the above object, the technical solution of the present invention is as follows:

[0009] The first aspect of the present invention provides a Lactobacillus reuteri ( Limosilactobacillus reuteri )HYZQF-1, deposited in Guangdong Microbiological Culture Collection Center (address: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou), the deposit date is July 8, 2024, and the deposit number is GDMCC NO: 64833.

[0010] The second aspect of the present invention provides a microbial agent comprising an active ingredient, wherein the active ingredient comprises the above-mentioned Lactobacillus reuteri HYZQF-1 or its inactivated bacteria, fermentation broth, and metabolites.

[0011] Furthermore, the microbial agent is a freeze-dried powder of inactivated bacterial metabolites.

[0012] The third aspect of the present invention provides a method for preparing the above-mentioned microbial agent, comprising the following steps:

[0013] S1, inoculating the Lactobacillus reuteri HYZQF-1 into an activation culture medium, and culturing at 35-40° C. for 20-25 hours to obtain an expanded bacterial culture liquid;

[0014] S2, inoculating the expanded bacterial culture liquid obtained in step S1 into the primary seed culture liquid, and culturing at 35-40° C. for 16-20 h to obtain the primary bacterial culture liquid;

[0015] S3, inoculating the primary bacterial liquid prepared in step S2 into a seed tank containing a seed culture medium under sterile conditions, with an inoculation amount of 1-5%, stirring culture at 110-130 r / min, natural pH, temperature 30-40°C, tank pressure 0.03-0.06 MPa, and culture for 11-13 h to obtain a seed tank bacterial strain;

[0016] S4, inoculating the seed tank strain into a fermentation tank containing sterilized fermentation culture medium, with an inoculation amount of 1-10%, 35-39°C, 70-90 r / min, tank pressure of 0.04-0.06 MPa, pH of 5.9-6.1, and fermenting for 24-26 h; cooling to 19-21°C, adding 1.9-2.1% sterile glycerol by volume of the fermentation liquid into the fermentation tank, raising the temperature to 119-121°C and maintaining for 5-7 s for inactivation treatment, to obtain.

[0017] Furthermore, after step S4 is completed, the obtained fermentation liquid is centrifuged to collect the inactivated wet bacterial sludge metabolites, and the inactivated wet bacterial sludge metabolites are freeze-dried to obtain freeze-dried powder of the inactivated bacterial metabolites.

[0018] The fourth aspect of the present invention provides the use of the above-mentioned Lactobacillus reuteri HYZQF-1 or the above-mentioned microbial agent in the preparation of any of the following products:

[0019] (1) Used to regulate intestinal flora and promote digestion;

[0020] (2) Used to increase catalase activity;

[0021] (3) Used to increase superoxide dismutase activity;

[0022] (4) Used to increase the activity of glutathione catalase;

[0023] (5) Used to sober up and protect the liver;

[0024] Among them, the use for sobering up and protecting the liver refers to having an auxiliary protective effect on chemical liver damage, and the chemical liver damage includes fatty liver, hepatitis, cirrhosis or liver cancer caused by alcohol;

[0025] The product is one of food and medicine.

[0026] The fifth aspect of the present invention provides the use of the above-mentioned Lactobacillus reuteri HYZQF-1 or the above-mentioned microbial agent in the preparation of a product for improving beneficial ingredients in the intestine, wherein the beneficial ingredients are one or more of mucopolysaccharides, ornithine, lactobacillus and lecithin; the product is one of a food and a medicine.

[0027] The sixth aspect of the present invention provides a product, which comprises the above-mentioned Lactobacillus reuteri HYZQF-1 or the above-mentioned microbial agent and an acceptable auxiliary agent or excipient.

[0028] Furthermore, the product is one of a food and a medicine; and the product is administered to a human or non-human mammal.

[0029] The beneficial effects of the present invention are:

[0030] The present invention screened and obtained a strain of Lactobacillus reuteri ( Limosilactobacillus reuteri )HYZQF-1, the deposit number is: GDMCC NO: 64833. Based on this Lactobacillus reuteri, a probiotic product has been successfully developed. It has been verified that it has the effect of regulating the balance of intestinal flora and promoting digestion and absorption, as well as the effect of sobering up and protecting the liver. Daily administration of 45 billion strains of the present invention and 300 mg of metabolites can continuously provide the endogenous necessary amount of mucopolysaccharides, ornithine, lactobacillus, and lecithin during the intestinal reproduction and growth process, which can sober up and protect the liver and maintain the health of the body.

[0031] The food or medicine containing Lactobacillus reuteri HYZQF-1 provided by the present invention can effectively alleviate the body's absorption of alcohol after taking it, thereby relieving and improving the discomfort after drinking, reducing the problems of headache, vomiting, dizziness, etc. after drinking, and further playing the role of sobering up and protecting the liver.

[0032] The preparation method of the microbial agent of the present invention is simple, and the food or medicine prepared by the preparation method of the present invention has the advantages of good alcohol sobering and liver protecting effects, no side effects, low cost, etc. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0034] Figure 1 Comparison of the number of spontaneous activities of mice in each group in Example 1;

[0035] Figure 2 Comparison of righting reaction of mice in each group in Example 1;

[0036] Figure 3 This is a comparison of the drunken sleep experiment of each group of mice in Example 1;

[0037] Figure 4 Comparison of liver coefficients of mice in each group in Example 1;

[0038] Figure 5 is the malondialdehyde level of each group of mice in Example 1;

[0039] Figure 6 Glutathione peroxidase and superoxide dismutase levels of mice in each group in Example 1;

[0040] Figure 7 Glutathione and catalase levels of mice in each group in Example 1;

[0041] Figure 8 is the glutamine aminotransferase level of each group of mice in Example 1;

[0042] Fig. 9 are the aspartate aminotransferase and alanine aminotransferase levels of mice in each group in Example 1;

[0043] Fig.10 is the cytokine level of each group of mice in Example 1;

[0044] Fig.11 This is the metabolomics analysis result of mouse feces in Example 1. DETAILED DESCRIPTION

[0045] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0046] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments of the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0047] A first typical embodiment of the present invention provides a Lactobacillus reuteri ( Limosilactobacillus reuteri )HYZQF-1, deposited in Guangdong Microbiological Culture Collection Center (address: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou), the deposit date is July 8, 2024, and the deposit number is GDMCC NO: 64833.

[0048] The bacteria was isolated from cheese in Xinjiang Uygur Autonomous Region and identified as Lactobacillus reuteri by 16srRNA method. The identification sequence is as follows:

[0049]

[0050] The Lactobacillus reuteri strain of the present invention is a probiotic strain approved for use by the National Health Commission. While regulating the balance of intestinal flora and promoting human digestion and absorption, the strain also has the effect of sobering up and protecting the liver. Daily administration of 45 billion strains of the present invention and 300 mg of metabolites can sustainably provide the endogenous necessary amount of mucopolysaccharides, ornithine, lactobacillus, and lecithin during the intestinal reproduction and growth process. It can sober up and protect the liver, and maintain the health of the body.

[0051] A second typical embodiment of the present invention provides a microbial agent, comprising an active ingredient, wherein the active ingredient comprises the above-mentioned Lactobacillus reuteri HYZQF-1 or its inactivated bacteria, fermentation broth, and metabolites.

[0052] The microbial agent comprises inactivated Lactobacillus reuteri HYZQF-1 and its fermentation liquid.

[0053] In some examples of this embodiment, the microbial agent is a lyophilized powder of its inactivated bacterial metabolites.

[0054] A third typical embodiment of the present invention provides a method for preparing the above-mentioned microbial agent, comprising the following steps:

[0055] S1. Activation of bacterial strains: inoculating the Lactobacillus reuteri HYZQF-1 into an activation culture medium, and culturing at 35-40° C. for 20-25 h to obtain an expanded bacterial strain liquid;

[0056] The activation medium is composed of: based on the weight of water added, 15-25 parts of L-arabinose, 1-10 parts of maltitol, 1-10 parts of beef extract powder, 0.1-2 parts of yeast extract powder, 0.1-2 parts of sodium acetate, 0.1-1 parts of Tween-80, 0.1-1 parts of potassium dihydrogen phosphate, 1000 parts of water, and the pH is adjusted to 7;

[0057] More specifically, based on the weight of water added, 20 g of L-arabinose, 2 g of maltitol, 2 g of beef extract powder, 1 g of yeast extract powder, 0.5 g of sodium acetate, 0.5 mL of Tween-80, 0.2 g of potassium dihydrogen phosphate, 1000 mL of tap water, and the pH was adjusted to 7.0 (alkaline solution adjustment).

[0058] S2. Preparation of primary bacterial seed solution: inoculate the expanded bacterial seed solution prepared in step S1 into the primary seed culture solution, and culture at 35-40° C. for 16-20 h to obtain the primary bacterial seed solution;

[0059] The composition of the primary seed culture solution is as follows: based on the weight of water added, 1-10 parts of L-arabinose, 1-10 parts of yeast peptone, 0.5-1.5 parts of beef extract powder, 1-2 parts of lactose, 0.5-1 part of sodium acetate, 0.5-1.5 parts of Tween-80, 1000 parts of water, and the pH value is natural;

[0060] More specifically, based on the weight of water added, L-arabinose 8 g, yeast peptone 6 g, beef extract powder 1 g, lactose 1.4 g, sodium acetate 0.8 g, Tween-80 1 mL, tap water 1000 mL, pH natural.

[0061] S3, seed tank strain preparation: the primary strain liquid prepared in step S2 is inoculated into a seed tank containing a seed culture medium under sterile conditions, the inoculation amount is 1-5%, the stirring culture is carried out at 110-130 r / min, the pH is natural, the temperature is 30-40°C, the tank pressure is 0.03-0.06 MPa, and the culture is carried out for 11-13 h to obtain the seed tank strain;

[0062] The composition of the seed tank culture medium is as follows: L-arabinose 1.0-5.0%, casein peptone 0.1-1.0%, dipotassium hydrogen phosphate 0.1-1.0%, onion juice powder 0.5-1.0%, sodium acetate 0.1-1.0%, ginger juice powder 0.1-1%, Tween-80 0.05-0.15%, polyether defoamer 0.05-0.15%, water 93-94%, pH value natural;

[0063] More specifically, L-arabinose 3%, casein peptone 0.9%, dipotassium hydrogen phosphate 0.4%, onion juice powder 0.8%, sodium acetate 0.7%, ginger juice powder 0.8%, Tween-80 0.1%, polyether defoamer 0.1%, tap water 93.2%, pH natural.

[0064] S4, Lactobacillus reuteri fermentation: inoculate the seed tank strain into a fermentation tank containing sterilized fermentation culture liquid, the inoculation amount is 1-10%, 35-39 ° C, 70-90 r / min, tank pressure is 0.04-0.06 MPa, pH is 5.9-6.1, and fermentation is carried out for 24-26 h; cool to 19-21 ° C, add 1.9-2.1% of the volume of the fermentation liquid sterile glycerol into the fermentation tank, raise the temperature to 119-121 ° C and keep for 5-7 s for inactivation treatment, and obtain;

[0065] The fermentation culture liquid is composed of: L-arabinose 1.0-5.0%, casein peptone 1.0-5.0%, trehalose 1.0-5.0%, stachyose 0.5-1.5%, yeast extract 1.0-5.0%, sodium acetate 0.5-1.5%, Tween-80 0.1-0.3%, kale powder 0.1-1.0%, dipotassium hydrogen phosphate 0.5-1.0%, polyether defoamer 0.05-0.15%, water 80-85%;

[0066] More specifically, L-arabinose 4%, casein peptone 3%, trehalose 2%, stachyose 1%, yeast extract powder 2.5%, sodium acetate 0.9%, Tween-80 0.2%, kale powder 0.6%, dipotassium hydrogen phosphate 0.9%, polyether defoamer 0.1%, and tap water 84.8%.

[0067] In some examples of this embodiment, after step S4 is completed, the obtained fermentation broth is centrifuged to collect the inactivated wet bacterial sludge metabolites, and the inactivated wet bacterial sludge metabolites are freeze-dried to obtain freeze-dried powder of the inactivated bacterial metabolites.

[0068] A fourth typical embodiment of the present invention provides the use of the above-mentioned Lactobacillus reuteri HYZQF-1 or the above-mentioned microbial agent in the preparation of any of the following products:

[0069] (1) Used to regulate intestinal flora and promote digestion;

[0070] (2) Used to increase catalase activity;

[0071] (3) Used to increase superoxide dismutase activity;

[0072] (4) Used to increase the activity of glutathione catalase;

[0073] (5) Used to sober up and protect the liver;

[0074] Among them, the use for sobering up and protecting the liver refers to having an auxiliary protective effect on chemical liver damage, and the chemical liver damage includes fatty liver, hepatitis, cirrhosis or liver cancer caused by alcohol;

[0075] The product is one of food and medicine.

[0076] A fifth typical embodiment of the present invention provides the use of the above-mentioned Lactobacillus reuteri HYZQF-1 or the above-mentioned microbial agent in the preparation of a product for enhancing beneficial ingredients in the intestine, wherein the beneficial ingredients are one or more of mucopolysaccharides, ornithine, lactobacillus and lecithin; the product is one of a food and a medicine.

[0077] A sixth typical embodiment of the present invention provides a product, which comprises the above-mentioned Lactobacillus reuteri HYZQF-1 or the above-mentioned microbial agent and an acceptable auxiliary agent or excipient.

[0078] In some examples of this embodiment, the product is one of a food and a medicine; and the subject to which the product is administered is a human or non-human mammal.

[0079] In some examples of this embodiment, the auxiliary agent or adjuvant may be a carrier, excipient, diluent, etc. commonly used in pharmacy. Moreover, according to the usual method, it can be made into an oral preparation in the form of powder, granule, capsule, tablet, pill, extract, liquid preparation, sugar or jelly, etc. The non-pharmaceutical active ingredients such as carrier, excipient, diluent, etc. that may be included are well known in the art, and a person of ordinary skill in the art can determine that they meet clinical standards.

[0080] In another specific embodiment of the present invention, the carrier, excipient and diluent include but are not limited to lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.

[0081] The term "food" used in the present invention can be in any form that can be eaten, including but not limited to beverages, dairy products, candy products, health foods, special dietary foods, special medical formula foods, etc.

[0082] The medicine may comprise a carrier, an excipient and a diluent, and its dosage form is an oral preparation in the form of powder, granules, tablets, capsules, suspensions, emulsions, syrups, sprays, or an injection in the form of a sterile injection solution.

[0083] The product can be a medicine, and the medicine can also contain an appropriate amount of commonly used carriers, excipients and diluents. Moreover, according to the usual method, it can be made into a dosage form in the form of an oral agent such as a powder, granules, tablets, capsules, suspensions, emulsions, syrups, sprays, and sterile injection solutions. The non-pharmaceutical active ingredients such as carriers, excipients and diluents that can be included in the present invention are well known in the art, and those of ordinary skill in the art can determine that they meet clinical standards.

[0084] The carrier, excipient and diluent of the present invention include, but are not limited to, lactose, glucose, sorbitol, mannitol, xylitol, maltitol, starch, gum arabic, gelatin, calcium phosphate, cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, and mineral oil, etc. No specific limitation is made here.

[0085] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.

[0086] In the examples, the "%" of the components in each culture medium (liquid) is the mass volume percentage, and the unit is g / mL. In the examples, the density of Tween-80 is 1.08 g / cm 3 .

[0087] The equipment used in production are as follows: culture incubator, clean bench, constant temperature incubator, various test tubes, triangular flasks, seed tanks, fermentation tanks, vacuum freeze dryer, three-dimensional mixer, low-temperature crusher, vacuum packaging machine.

[0088] Example 1: A microbial agent with alcohol sobering and liver protecting effects

[0089] The strain used in this example is named Lactobacillus reuteri HYZQF-1, which is deposited in Guangdong Microbiological Culture Collection Center (address: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou), with a deposit date of July 8, 2024 and a deposit number of GDMCC NO: 64833.

[0090] (1) Bacteria activation:

[0091] Bacterial strain culture: Expansion culture of bacterial strains preserved in -80℃ refrigerator.

[0092] Preparation of culture medium: 20 g L-arabinose, 2 g maltitol, 2 g beef extract powder, 1 g yeast extract powder, 0.5 g sodium acetate, 0.5 mL Tween-80, 0.2 g potassium dihydrogen phosphate, 1000 mL tap water, pH adjusted to 7.0 (alkaline solution adjustment).

[0093] Operation: Add L-arabinose and other raw materials in the above formula into 1000 mL of water in the formula without any particular order, stir for 10 minutes to dissolve, and then divide into test tubes, each test tube contains 5 mL, seal with kraft paper and place in a medical sterilizer for sterilization at 0.1-0.12 MPa for 20 minutes. The culture medium is ready.

[0094] Inoculation: Under sterile conditions (clean bench), open the -80℃ low-temperature freezer to store the frozen tube of bacteria, and dissolve it at room temperature. Then take one sterilized test tube culture medium, add 0.5 mL of the dissolved bacterial solution into the test tube, seal the tube mouth with kraft paper, shake it gently by hand, and place it in a constant temperature incubator at 37℃ for 24 hours. This is called expansion culture medium.

[0095] (2) Preparation of primary bacterial culture liquid:

[0096] Primary seed culture formula: L-arabinose 8 g, yeast peptone 6 g, beef extract powder 1 g, lactose 1.4 g, sodium acetate 0.8 g, Tween-80 1 mL, tap water 1000 mL, pH natural.

[0097] Operation: Add the above raw materials into 1000 mL of tap water without any distinction, start the blender, and stir for 10 minutes to dissolve them all. This is called the primary seed culture solution.

[0098] Add the stirred and dissolved first-level seed culture solution into the conical flask according to the dosage, then wrap the bottle mouth with 6 layers of gauze and one layer of kraft paper, and put it into the sterilizer for sterilization. Before sterilization, first open the exhaust valve on the sterilizer and close it when a small amount of steam is discharged. When the pressure on the sterilizer reaches 0.05 MPa, open the exhaust valve on the sterilizer to exhaust for 6-8 minutes, then close the exhaust valve and continue heating. When the steam pressure in the sterilizer reaches 0.1-0.12 MPa, start timing. The sterilization time is 20 minutes. After completion, leave the heat source and let it cool down naturally. When the pressure gauge on the sterilizer returns to zero, open the sterilizer, take out the sterilized culture medium and put it into the clean bench for natural cooling. When the temperature drops to 37°C, transfer the above cultured expansion culture solution to the sterilized culture solution in the conical flask. The inoculation amount is 0.5%, that is, 100 mL of first-level seed culture solution and 0.5 mL of expansion culture solution. mL. After completion, seal the bottle mouth with the original gauze and kraft paper, shake it slightly by hand to mix the inoculated bacteria and culture solution evenly, and then place it in a constant temperature box and culture it at 37°C for 18 hours. This is called the primary culture solution.

[0099] (3) Preparation of seed tank strains:

[0100] Sterilization of fermentation equipment, pipelines and sterile filtration systems:

[0101] First, open the valves of all inlet and outlet pipelines and sterile air pipelines, and pass 0.12-0.14 MPa steam. Allow the steam to connect with the pipeline valves and discharge a small amount of steam. Ventilate for 40 minutes, then close the valves of all inlet and outlet pipelines and set aside.

[0102] Sterilization of empty seed tanks and fermentation tanks:

[0103] Close all valves, open the drain valve at the bottom of the tank and the drain valve in the tank interlayer, open the direct steam valve to introduce 0.12-0.14 MPa steam into the pipe, start timing when the temperature in the tank reaches 121°C, the sterilization time is 40 min, then close the drain valve at the bottom of the tank and the drain valve in the interlayer, and the temperature in the tank will naturally drop to 37°C for standby use.

[0104] Seed pot culture:

[0105] Formula: L-arabinose 3%, casein peptone 0.9%, dipotassium hydrogen phosphate 0.4%, onion juice powder 0.8%, sodium acetate 0.7%, ginger juice powder 0.8%, Tween-80 0.1%, polyether defoamer 0.1%, tap water 93.2%, natural pH value.

[0106] Specific operation: First, pour the tap water used in the formula into the sterilized seed tank, start the mixer, add the raw materials required in the formula respectively (the order of addition is not important), then stir continuously and pass steam for heating. First, use the steam in the tank interlayer to heat to 95°C, then switch to direct steam heating. When the temperature in the tank reaches 121°C, maintain it for 20 minutes to achieve the sterilization effect, then turn off the steam, and start cooling through the tap water in the tank interlayer. When the temperature in the tank reaches 37°C, it is ready for use. This is called seed culture medium. Then inoculate the above-cultured first-level bacterial culture solution into the seed tank under sterile conditions. The inoculation amount is 3% of the culture medium in the tank. 100 kg of seed tank culture medium can be inoculated with 3 kg of first-level bacterial solution. Then cover the inoculation cap on the tank and start stirring and culturing. The culture conditions are: temperature 37°C, natural pH value, stirring speed 120 r / min, tank pressure 0.05 MPa, and culture time 12 hours to meet the requirements. If the tank body is lowered, sterile air can be introduced to maintain the tank pressure. If the tank pressure is too high, the air release valve on the tank top can be used to adjust it. This is called seed tank culture.

[0107] (4) Lactobacillus reuteri fermentation:

[0108] Culture medium formula: L-arabinose 4%, casein peptone 3%, trehalose 2%, stachyose 1%, yeast extract powder 2.5%, sodium acetate 0.9%, Tween-80 0.2%, kale powder 0.6%, dipotassium hydrogen phosphate 0.9%, polyether defoamer 0.1%, tap water 84.8%.

[0109] Specific operation: First, add the tap water used in the formula into the sterilized fermentation tank, start the mixer, add the raw materials used in the formula into the fermentation tank (the order of addition is not important), and then pass steam for heating. First, use the interlayer steam to heat to 95°C, and then switch to direct steam heating. When the temperature in the tank reaches 121°C, start timing, and keep it for 30 minutes to achieve the sterilization effect, and then cool it down with the tap water in the interlayer. When the temperature in the tank drops to 37°C, start to inoculate the strain. Before inoculation, first increase the tank pressure of the seed tank to 0.1 MPa, and keep the tank pressure of the fermentation tank at 0.05MPa, then open the inoculation pipeline valve, and transport the seeds cultured in the seed tank to the fermentation tank by pressure difference, and then close the inoculation channel valve.

[0110] The inoculation amount is 5 kg of the culture medium in the seed tank for every 100 kg of the fermentation tank. The culture conditions are: culture temperature 37℃, stirring speed 160 r / min, tank pressure maintained at 0.05 MPa, and the pH value is maintained at 6.0 through the acid and alkali automatic control system during the fermentation process. If the tank pressure decreases, sterile air can be introduced to maintain the tank pressure until the fermentation is completed. The total fermentation time is 25 hours, and then the temperature is lowered to 20℃, which is the fermentation liquid. UHT inactivation treatment is carried out at 120℃ for 6 seconds.

[0111] (5) Centrifugation of fermentation broth:

[0112] The fermentation liquid is pumped into a storage tank for centrifugation. Operation: Start the centrifuge, adjust the speed to 10000 r / min, centrifuge at a feed rate of 3kg / min, collect the inactivated wet bacterial sludge metabolites after centrifugation, and freeze-dry the collected inactivated wet bacterial sludge metabolites.

[0113] (6) Freeze-drying of bacterial sludge metabolites:

[0114] Preparation of bacterial suspension: Take 1000 g of inactivated wet bacterial sludge metabolites, add 4000 mL of sterile saline, 600 g of skimmed milk powder, 2000 g of L-arabinose, 30 g of D-pantothenic acid, and 60 g of inositol.

[0115] Operation: First, take 2500 mL of saline in the formula, add L-arabinose and stir to dissolve, then add 1000 g of inactivated wet bacterial sludge metabolites, then add the remaining saline, skim milk powder and auxiliary materials in the formula and stir well, which is called suspension. The suspension is freeze-dried and the moisture content is finally controlled to 4%, which is the inactivated bacterial metabolite freeze-dried powder. According to the test, the inactivated bacterial metabolite freeze-dried powder has an extracellular polysaccharide content of 28%, a polypeptide content of 7%, an amino acid content of 27%, and an inactivated bacterial cell content of 150 billion / g.

[0116] The inactivated bacteria of freeze-dried powder will be lost or broken during the dilution process. Although the bacteria are broken, the effect of the strain will not be weakened.

[0117] The freeze-dried powder can be widely used in food, baked food, solid beverages, liquid beverages, and compressed candies.

[0118] The freeze-dried powder prepared by the above method was subjected to the following effect verification.

[0119] 1. Experiment on the effect of alcohol detoxification and liver protection in mice

[0120] (1) Experimental animals

[0121] Fifty SPF mice, half male and half female, were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd.

[0122] (2) Reagents

[0123] Probiotic products: The freeze-dried powder prepared in Example 1 was configured into probiotic solutions of different concentrations. The probiotic solutions were prepared by weighing 10 mg (experimental group 1), 20 mg (experimental group 2), and 30 mg (experimental group 3) of the probiotic products and dissolving them in 0.5 mL of sterilized water for later use.

[0124] 52% (V / V) Red Star Erguotou (Beijing Red Star Co., Ltd.); the amount of alcohol used was determined based on previous experiments. When administered intragastrically at 0.15 mL / 10 g body weight, the animals became obviously intoxicated without causing massive mortality. When administered intragastrically at 0.05 mL / 10 g, the animals showed symptoms of intoxication but were able to move normally.

[0125] Alanine aminotransferase (ALT) kit (Nanjing Jiancheng Bioengineering Institute)

[0126] (3) Experimental groups

[0127] The experimental mice were randomly divided into 5 groups: control group, model group, and experimental group (divided into 3 groups, experimental group 1, experimental group 2, and experimental group 3), with 10 mice in each group. They were fasted for 12 hours before the experiment, but were not deprived of water.

[0128] (4) Autonomous activity experiment

[0129] The mice were pre-fed for 10 days. The experiment began on the 11th day. Before the experiment, the mice were placed in the spontaneous activity instrument for 10 minutes to adapt to the environment and ensure the accuracy of the experimental data. During the experiment, the experimental group was gavaged with the probiotic solution (0.5 mL) prepared in step (1), and the control group and the model group were gavaged with an equal volume of sterile water. After 30 minutes, the mice in the experimental group and the model group were gavaged with 52% (v / v) Red Star Erguotou at a rate of 0.05 mL / 10 g body weight, and the mice in the control group were gavaged with an equal volume of sterile water. The mice in each group were placed in the spontaneous activity instrument for 10 minutes in turn, and the number of spontaneous activities of the mice within 5 minutes was recorded. The results are shown in the table. Figure 1 .

[0130] (5) Righting experiment

[0131] On the 13th day, the experimental group was gavaged with the probiotic solution (0.5 mL) prepared in step (1), and the control group and the model group were gavaged with an equal volume of sterile water. 30 min later, the experimental group and the model group mice were gavaged with 0.15 mL / 10 g body weight of 52% (v / v) Red Star Erguotou, and the control group mice were gavaged with an equal volume of sterile water. The disappearance time and recovery time of the righting reaction of each group of mice were recorded, and the tolerance time (min, from the injection of wine to the disappearance of the righting reaction) and the duration (min, from the disappearance of the righting reaction to the recovery) were calculated. The results are shown in Figure 2 .

[0132] (6) Drunk sleep experiment

[0133] On the 15th day, the experimental group was gavaged with the probiotic solution (0.5 mL) prepared in step (1), while the control group and the model group were gavaged with an equal volume of sterile water. 30 min later, the mice in the experimental group and the model group were gavaged with 0.15 mL / 10 g body weight of 52% (v / v) Red Star Erguotou, while the mice in the control group were gavaged with an equal volume of sterile water. The activity of the mice was observed, and the indicators of sleep (drunkenness) were unsteady crawling, dragging of the back abdomen on the ground, and laziness with eyes closed, while the indicators of awakening (sobering up) were free movement, flexible limbs, and mental recovery. The time of falling asleep and waking up of the mice in each group were recorded, and the sleep latency (min, the time from gavage to falling asleep) and duration (min, the time from falling asleep to waking up) were calculated. The results are shown in the table below. Figure 3 .

[0134] (7) Biochemical index detection

[0135] Starting from the 17th day, in addition to normal feeding, the mice in the experimental group were gavaged with the probiotic solution (0.5 mL) prepared in step (1) at the same time every morning, and the control group and the model group were gavaged with an equal volume of sterile water. 30 minutes later, the mice in the experimental group and the model group were gavaged with 52% (v / v) Red Star Erguotou at 0.15 mL / 10 g body weight, and the mice in the control group were gavaged with an equal volume of sterile water for 6 consecutive weeks. After fasting for 12 h, the mice in each group were weighed, blood was collected from their eye sockets, and the serum was separated by centrifugation and stored at -80°C for later use.

[0136] The mice in each group were killed by cervical dislocation, and the liver was removed and weighed. The liver coefficient of the mice was calculated according to the following formula. The results are shown in Figure 4 .

[0137] Liver coefficient (%) = liver wet mass (g) / body mass (g) × 100

[0138] A certain amount of liver tissue was taken and prepared into tissue homogenates of different concentrations. The activities of malondialdehyde (MDA), glutathione (GSH), glutamine transaminase (TG), glutathione peroxidase (GSH-Px), superoxide dismutase (T-SOD) and catalase (CAT) were detected according to the operating procedures of the kit. The results are shown in Figure 5 , Figure 6 , Figure 7 , Figure 8 The activities of ALT and AST in mouse serum were measured by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) biochemical detection kits, respectively. The results are shown in Fig. 9According to the instructions of the ELISA kit, the levels of cytokines IL-1β, IL-6, and TNF-α in serum were determined. The results are shown in Fig.10 .

[0139] A small amount of alcohol has a certain stimulating effect on the brain of mice, which can make the brain excited and increase autonomous activity. Figure 1 It can be seen that the number of autonomous activities of mice in the experimental group within a certain period of time was significantly lower than that of mice in the model group, indicating that probiotics have a certain alleviating effect on alcohol stimulation. Figure 2 , Figure 3 It can be seen that compared with the mice in the model group, the righting reaction tolerance time and sleep latency time of the experimental group mice were significantly increased, and the duration of both was significantly reduced, indicating that probiotics have the effect of sobering up and preventing drunkenness under experimental conditions, and the effect is more obvious.

[0140] The liver coefficient can reflect the degree of liver damage. Figure 4 It can be seen that the liver coefficient of the experimental group mice was significantly lower than that of the model group mice, indicating that probiotics can protect the liver; GSH, T-SOD and CAT can reflect the body's antioxidant capacity and indirectly reflect the lipid peroxidation damage to liver cells. Figure 5 , Figure 6 , Figure 7 It can be seen that compared with the blank control group, the GSH content, GSH-Px, T-SOD, and CAT activities in the liver tissue of the model group were significantly reduced, and the MDA content was greatly increased. Compared with the model group, the GSH content in the experimental group was significantly increased, the GSH-Px, T-SOD, and CAT activities were increased, and the MDA content was significantly decreased, indicating that probiotics can reduce the accumulation of peroxidation products and the level of ROS in liver cells, enhance the body's ability to scavenge free radicals, and promote the production of antioxidants in the liver, thereby reducing the oxidative damage caused by alcohol to the liver; when the TG content is too high, it will cause fat to deposit in liver cells, affecting liver lipid metabolism and causing fatty liver and other diseases. According to Figure 8 It can be seen that compared with the model group, the TG content in the liver of the experimental group decreased, which indicates that probiotics can improve the lipid metabolism disorder caused by alcohol and have a good liver protection effect; the levels of ALT and AST in the blood are often used to evaluate the degree of liver damage. Fig. 9 It can be seen that compared with the control group, the ALT and AST activities in the serum of the model group mice were significantly increased. Compared with the model group, the ALT and AST activities in the experimental group were significantly reduced. This result shows that probiotics play a certain protective role against acute liver damage caused by heavy drinking; proinflammatory factors and inflammatory mediators will further lead to liver cell necrosis and apoptosis, damage the liver, and promote liver fibrosis. Fig.10It can be seen that compared with the control group, the levels of IL-1β, IL-6, and TNF-α in the serum of the model group were significantly increased, and compared with the model group, the levels of IL-1β, IL-6, and TNF-α in the experimental group were significantly decreased. This result shows that probiotics can reduce the levels of inflammatory factors TNF-α, IL-6, and IL-1β in the serum of mice in the model group, alleviate the inflammatory response caused by large amounts of alcohol intake, show good anti-inflammatory effects, and thus play a role in protecting the liver.

[0141] 2. Experiment on regulating the function of intestinal flora in mice

[0142] The mice were divided into a control group and an experimental group, with 10 mice in each group. The control group was fed normally, while the experimental group was fed normally. 30 mg of the above-mentioned freeze-dried powder of the inactivated bacterial metabolite was dissolved in 0.5 mL of sterile water to prepare a solution for gavage. After 30 days of feeding, the mouse feces were aseptically collected, weighed, diluted 10 times with sterile diluent to make a uniform suspension, and then diluted 10 times in turn. The appropriate dilution was selected and inoculated on each selective culture medium. The number of bacteria per gram of wet feces was calculated, and the logarithm was taken for statistical processing. 24 hours after the last administration of the probiotic product, rectal feces were taken to detect intestinal flora. The test results are shown in Table 1.

[0143] Table 1 Suitable culture conditions and detection of intestinal flora (x-±SD)

[0144]

[0145] As can be seen from Table 1, probiotics can increase the number of beneficial bacteria (Bifidobacterium and Lactobacillus), while the number of harmful bacteria (Enterobacter, Enterococcus) did not increase but showed a slight downward trend, indicating that probiotics have the function of regulating the intestinal flora of mice.

[0146] 3. Experiment on the effect of probiotics on gastrointestinal motility in mice

[0147] The mice were divided into a control group, a model group and an experimental group, with 10 mice in each group. The control group and the model group were given 0.5 mL of sterile water by gavage once a day; the experimental group was given a solution of a probiotic product (30 mg dissolved in 0.5 mL of sterile water) (i.e., the lyophilized powder prepared in Example 1) by gavage once a day. After 15 days of gavage, the mice in each group fasted for 16 hours. After that, the model group and the experimental group were given compound difenoxol by gavage, and the control group was given distilled water by gavage. After 30 minutes, the mice in each group were given Arabic gum ink by gavage. After 30 minutes, the mice were killed by cervical vertebral dissection, and the abdomen was quickly cut along the midline of the abdomen to separate the mesentery. The intestinal tube was cut with the pylorus as the starting point and the ileocecal part as the end point. The small intestine was gently pulled into a straight line, and the intestinal tube length was measured as the "total length of the small intestine", and the length from the pylorus to the front of the ink was the "ink advancement length". The ink advancement rate was calculated according to the following formula. The ink advancement rate of the small intestine is shown in Table 2.

[0148]

[0149] Table 2 Small intestinal ink propulsion rate (x - ±SD)

[0150]

[0151] As shown in Table 2, the intestinal motility inhibition model of mice was established by administering compound difenocool. Compared with the model group, the small intestinal ink propulsion rate increased in the experimental group, indicating that probiotics can promote small intestinal motility and digestion.

[0152] 4. Metabolomics analysis

[0153] Metabolomics analysis of mouse feces was performed using ultra-performance liquid chromatography-tandem mass spectrometry.

[0154] Experimental plan: The mice were divided into a control group and an experimental group. The control group was fed normally, while the experimental group was fed normally and gavaged with 30 mg of the solution prepared by the freeze-dried powder of the above-mentioned inactivated bacterial metabolites. After feeding for 90 days, fecal samples of the mice in the control group and the experimental group were placed in 400 μL of extraction solution (acetonitrile: methanol = 1: 1), vortexed for 30 s, and extracted with low-temperature ultrasound for 30 min (5℃, 40 KHz), allowed to stand at -20℃ for 30 min, placed in a 4℃ centrifuge, centrifuged at 13000 r / min for 15 min, the supernatant was taken, dried with nitrogen, re-dissolved with 120 μL of the reconstitution solution (acetonitrile: water = 1: 1), extracted with low-temperature ultrasound for 5 min (5℃, 40 KHz), placed in a 4℃ centrifuge, centrifuged at 13000 r / min for 5 min, and an appropriate amount of supernatant was taken for analysis. 10uL of sample supernatant was separated by BEH C18 column (100mm ×2.1mm, 1.8µm) and then entered mass spectrometry detection. The separation flow rate was 0.40mL / min and the column temperature was 40℃. After completion, the LC-MS raw data was transferred to the computer for processing and analysis. The MS mass spectrum information was matched with the public database to obtain the main metabolite information such as Fig.11 As shown, the contents of the main metabolites were determined, and the results are shown in Table 3.

[0155] Among them, the method for detecting the mucopolysaccharide content is spectrophotometry; the method for detecting the ornithine content is high performance liquid chromatography; the method for detecting the lactobacillus content is high performance liquid chromatography; and the method for detecting the lecithin content is high performance liquid chromatography.

[0156] Table 3 Contents of main metabolites in mice

[0157]

[0158] It can be seen from Table 3 that daily administration of 30 mg of a probiotic product containing 4.5 billion inactivated bacteria and metabolites to mice can significantly increase the contents of mucopolysaccharides, ornithine, lactobacillus, and lecithin in the feces of the mice, indicating that the probiotic product provided by the present invention can sustainably provide the endogenously required amount of mucopolysaccharides, ornithine, lactobacillus, and lecithin during the intestinal reproduction and growth process.

[0159] 5. Small-scale clinical trials

[0160] The subjects were people with alcoholic liver disease with an average age of 48 years old from 8 communities in Jinan City. As of June 2019, a total of 80 people were recruited to participate in the experiment. The subjects took 0.3 grams of the probiotic product (i.e., the freeze-dried powder prepared in Example 1) once a day before going to bed. All of the above-mentioned persons signed a written informed consent form. If the participant was unable to sign, the agent (usually a family member) signed it.

[0161] Table 4 Population situation of alcohol detoxification and liver protection

[0162]

[0163] Table 4 Description:

[0164] Alcoholic fatty liver: 20 people started to collect the results after taking it for 8 days. After taking it for 8 days, 5 people felt that their abdominal pain, loss of appetite, fatigue, and angular cheilitis improved. After taking it for 16 days, 8 people felt that their abdominal pain, loss of appetite, fatigue, and angular cheilitis improved significantly. After taking it for 24 days, 14 people felt that their abdominal pain, loss of appetite, fatigue, and angular cheilitis improved extremely significantly. After taking it for 30 days, 18 people felt that their abdominal pain, loss of appetite, fatigue, and angular cheilitis were completely improved. A total of 2 people did not improve after taking Lactobacillus reuteri.

[0165] Alcoholic hepatitis: 20 people started to collect the results after taking it for 15 days. After taking it for 15 days, 6 people felt that their abdominal distension, general fatigue, loss of appetite, diarrhea, nausea, vomiting, abdominal pain, fever, jaundice, hepatomegaly and tenderness improved. After taking it for 30 days, 9 people felt that their abdominal distension, general fatigue, loss of appetite, diarrhea, nausea, vomiting, abdominal pain, fever, jaundice, hepatomegaly and tenderness improved significantly. After taking it for 45 days, 14 people felt that their abdominal distension, general fatigue, loss of appetite, diarrhea, nausea, vomiting, abdominal pain, fever, jaundice, hepatomegaly and tenderness improved extremely significantly. After taking it for 60 days, 17 people felt that their abdominal distension, general fatigue, loss of appetite, diarrhea, nausea, vomiting, abdominal pain, fever, jaundice, hepatomegaly and tenderness were completely improved. A total of 3 people did not improve after taking Lactobacillus reuteri.

[0166] Alcoholic cirrhosis: 20 people started to collect the results after taking the medicine for 22 days. After taking it for 22 days, 4 people felt that their loss of appetite, abdominal pain, fatigue, tiredness, dark urine, bleeding gums and nose bleeding had improved. After taking it for 46 days, 8 people felt that their loss of appetite, abdominal pain, fatigue, tiredness, dark urine, bleeding gums and nose bleeding had improved significantly. After taking it for 69 days, 13 people had extremely obvious improvements in their loss of appetite, abdominal pain, fatigue, tiredness, dark urine, bleeding gums and nose bleeding. After taking it for 90 days, 16 people had completely improved their loss of appetite, abdominal pain, fatigue, tiredness, dark urine, bleeding gums and nose bleeding. A total of 4 people did not improve after taking Lactobacillus reuteri.

[0167] Alcoholic liver cancer: 20 people started to collect the results after taking the medicine for 45 days. After taking it for 45 days, 3 people felt that the pain, bloating, fatigue and other conditions in the liver area had improved. After taking it for 90 days, 8 people felt that the pain, bloating, fatigue and other conditions in the liver area had improved significantly. After taking it for 135 days, 14 people felt that the pain, bloating, fatigue and other conditions in the liver area had improved significantly. After taking it for 180 days, 15 people had completely improved their pain, bloating, fatigue and other conditions in the liver area, and their liver function returned to normal after taking it for 200 days. A total of 5 people did not improve after taking Lactobacillus reuteri.

[0168] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A Lactobacillus reuteri ( Limosilactobacillus reuteri )HYZQF-1, characterized in that, The Lactobacillus reuteri HYZQF-1 strain was deposited in the Guangdong Provincial Microbiological Culture Collection Center on July 8, 2024, and the collection number is GDMCC NO: 64833.

2. A microbial agent, characterized in that: The invention comprises active ingredients, wherein the active ingredients comprise the Lactobacillus reuteri HYZQF-1 and fermentation liquid thereof according to claim 1.

3. The microbial agent according to claim 2, characterized in that The microbial agent comprises inactivated Lactobacillus reuteri HYZQF-1 and its fermentation liquid.

4. The microbial agent according to claim 2, characterized in that The microbial agent is freeze-dried powder.

5. The method for preparing the microbial agent according to any one of claims 2 to 4, characterized in that: The following steps are involved: S1. Activation of bacterial strains: inoculating the Lactobacillus reuteri HYZQF-1 into an activation culture medium, and culturing at 35-40° C. for 20-25 h to obtain an expanded bacterial strain liquid; S2. Preparation of primary bacterial seed solution: inoculate the expanded bacterial seed solution prepared in step S1 into the primary seed culture solution, and culture at 35-40° C. for 16-20 h to obtain the primary bacterial seed solution; S3, seed tank strain preparation: the primary strain liquid prepared in step S2 is inoculated into a seed tank containing a seed culture medium under sterile conditions, the inoculation amount is 1-5%, the stirring culture is carried out at 110-130 r / min, the pH is natural, the temperature is 30-40°C, the tank pressure is 0.03-0.06 MPa, and the culture is carried out for 11-13 h to obtain the seed tank strain; S4, Lactobacillus reuteri fermentation: inoculate the seed tank strain into a fermentation tank containing sterilized fermentation culture medium, with an inoculation amount of 1-10%, 35-39°C, 70-90 r / min, tank pressure of 0.04-0.06 MPa, pH of 5.9-6.1, and ferment for 24-26 h; cool to 19-21°C, add sterile glycerol of 1.9-2.1% of the volume of the fermentation liquid into the fermentation tank, raise the temperature to 119-121°C and maintain for 5-7 s for inactivation treatment, and obtain.

6. The preparation method according to claim 5, characterized in that: After step S4 is completed, the obtained fermentation liquid is centrifuged to collect the inactivated wet bacterial sludge metabolites, and the inactivated wet bacterial sludge metabolites are freeze-dried to obtain freeze-dried powder of the inactivated bacterial metabolites; In step S1, the composition of the activation medium is as follows: based on the weight of water added, 15-25 parts of L-arabinose, 1-10 parts of maltitol, 1-10 parts of beef extract powder, 0.1-2 parts of yeast extract powder, 0.1-2 parts of sodium acetate, 0.1-1 parts of Tween-80, 0.1-1 parts of potassium dihydrogen phosphate, 1000 parts of water, and the pH is adjusted to 7; In step S2, the composition of the primary seed culture solution is as follows: 1-10 parts of L-arabinose, 1-10 parts of yeast peptone, 0.5-1.5 parts of beef extract powder, 1-2 parts of lactose, 0.5-1 parts of sodium acetate, 0.5-1.5 parts of Tween-80, 1000 parts of water, and the pH value is natural; In step S3, the composition of the seed tank culture medium is as follows: L-arabinose 1.0-5.0%, casein peptone 0.1-1.0%, dipotassium hydrogen phosphate 0.1-1.0%, onion juice powder 0.5-1.0%, sodium acetate 0.1-1.0%, ginger juice powder 0.1-1%, Tween-800.05-0.15%, polyether defoamer 0.05-0.15%, water 93-94%, pH value natural; In step S4, the fermentation culture medium is composed of: L-arabinose 1.0-5.0%, casein peptone 1.0-5.0%, trehalose 1.0-5.0%, stachyose 0.5-1.5%, yeast extract 1.0-5.0%, sodium acetate 0.5-1.5%, Tween-80 0.1-0.3%, kale powder 0.1-1.0%, dipotassium hydrogen phosphate 0.5-1.0%, polyether defoamer 0.05-0.15%, and water 80-85%.

7. Use of the Lactobacillus reuteri HYZQF-1 according to claim 1 or the microbial agent according to any one of claims 2 to 4 in the preparation of any of the following products: (1) It helps regulate intestinal flora and aids digestion; (2) Used to sober up and protect the liver; in, It is used for alcohol sobering up and protecting the liver, which means it has an auxiliary protective effect on chemical liver damage caused by alcohol; The product is one of food and medicine.

8. A product, characterized in that The invention comprises the Lactobacillus reuteri HYZQF-1 as described in claim 1, or the microbial agent as described in any one of claims 2 to 4, and an acceptable adjuvant or auxiliary material; the product is one of a food and a medicine; and the product is administered to a human or non-human mammal.

Images